Italian Medicines Agency Agenzia Italiana del Farmaco

Vaccines included in Law no. 119/2017 and meningococcal A, C, W, Y vaccines: checks on the immediate packaging and absence of latex - Vaccines included in Law no. 119/2017 and meningococcal A, C, W, Y vaccines: checks on the immediate packaging and absence of latex

Asset Publisher

Vaccines included in Law no. 119/2017 and meningococcal A, C, W, Y vaccines: checks on the immediate packaging and absence of latex

AIFA has published information on the absence of latex/natural rubber from the different components of the immediate packaging (pre-filled syringes: e.g. cylinder, piston and seal, tip cover, protective needle cover cap, etc.; glass vials: e.g. stopper, cap; oral tubes and applicators) of mandatory and free vaccines as well as of non-mandatory, free and actively offered vaccines provided for in Law no. 119/2017 and authorised in Italy. This follows the necessary checks with marketing authorisation holders (MAHs).

This information is extremely important for those people who are allergic to natural rubber latex and need to receive a vaccine. In fact, the presence of latex, even in traces, in the vaccine would expose such people to the risk of allergic reactions.

The European Commission guideline on excipients in the labelling and package leaflet of medicinal products for human use provides for the inclusion of a warning (‘The container of this medicinal product contains latex rubber. May cause severe allergic reactions’) in the package leaflet (PL), should latex/natural rubber be present in any quantity, regardless of the route of administration of the medicinal product.

If latex/natural rubber is not present, the inclusion of a specific warning in the PL is not required.

In addition to these provisions, AIFA has considered it appropriate to contact the MAHs of the above-mentioned vaccines, asking to confirm the absence of latex/natural rubber from the different components of the immediate packaging, in case no specific warning is included in the Summary of Product Characteristics (SmPC) and Patient Leaflet.

Based on the statements made by the MAHs and on the information included in the SmPC/PL of these vaccines, AIFA provides summary information ("Related documents"). 

Please note that not all vaccines (and/or their packs and formulations) may be currently marketed in Italy.

The asterisk (*) indicates those vaccines for which the presence of latex/natural rubber cannot be excluded.


Published on: 17 February 2021

Asset Publisher

Asset Publisher

Galleria

Nested Applications

Last tweets

🎙️ “Immagino un futuro in cui ciascuno di noi abbia un vero e proprio passaporto farmacogenetico, m...
Vai al post →
💊 Quasi 4 cittadini su 10 hanno ricevuto almeno una prescrizione di #antibiotici nel 2024, con una ...
Vai al post →
⚠️ Attenzione alle false cure miracolose Negli ultimi tempi si sta diffondendo un business pericol...
Vai al post →
#AIFA promuove l’ascolto e la trasparenza Approvati i Regolamenti di “AIFA Ascolta” e “AIFA Incontr...
Vai al post →
Oggi si celebra il #WorldAutismAwarenessDay. 🔵 L'Agenzia Italiana del Farmaco sostiene la Giornata...
Vai al post →
Jelena Ivanovic, dirigente medico dell’Ufficio Procedure Europee di #HTA di #AIFA, è stata eletta Co...
Vai al post →

Go to Twitter profile

Multimedia

Medicina di precisione e appropriatezza prescrittiva

Go to YouTube channel

Cookie Bar

cookie management module

Descrizione cookieBar

Questo sito utilizza cookie tecnici e analytics, necessari al suo funzionamento, per i quali non è richiesto il consenso. Per alcuni servizi aggiuntivi, le terze parti fornitrici, dettagliatamente sotto individuate, possono utilizzare cookies tecnici, analytics e di profilazione. Per saperne di più consulta la PRIVACY POLICY. Per proseguire nella navigazione devi effettuare la scelta sui cookie di terze parti dei quali eventualmente accetti l’utilizzo. Chiudendo il banner attraverso la X in alto a destra rifiuti tutti i cookie di terze parti. Puoi rivedere e modificare le tue scelte in qualsiasi momento attraverso il link "Gestione cookie" presente nel footer.

Social networks
go to beginning of content